Optimal first-line treatment for advanced thymic carcinoma

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Thymic carcinomas (TCs) are rare, aggressive thoracic malignancies.
• Currently, no standard first-line treatment exists for advanced TC.
• This study investigates optimal chemotherapy regimens for advanced TC.

Purpose of the Study:

• To determine the optimal chemotherapy regimen for advanced thymic carcinoma.
• To evaluate the impact of surgical resection and radiotherapy on progression-free survival in advanced TC.

Main Methods:

• Retrospective analysis of 67 patients with stage IV TC (2006-2015).
• Comparison of paclitaxel-platinum versus gemcitabine-platinum chemotherapy regimens.
• Multivariate Cox regression analysis to identify factors influencing progression-free survival (PFS).

Main Results:

• Gemcitabine-platinum yielded a median PFS of 12 months, compared to 7.0 months for paclitaxel-platinum (P=0.030).
• Surgical resection was associated with a median PFS of 18.0 months versus 7.3 months without resection (P=0.030).
• Radiotherapy was associated with a median PFS of 13.0 months versus 4.3 months without radiotherapy (P=0.001).

Conclusions:

• Gemcitabine-platinum and paclitaxel-platinum regimens are effective for advanced TC.
• Primary lesion resection and radiotherapy may offer survival benefits for selected advanced TC patients.